Calendrier des promotions Denali Therapeutics Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Denali Therapeutics Inc.
Denali Therapeutics Inc., биофармацевтическая компания, обнаруживает и разрабатывает терапевтические кандидаты от нейродегенеративных заболеваний в Соединенных Штатах. Компания предлагает продукты-кандидаты в ингибиторы богатых лейцином повторов киназы 2 (LRRK2), включая DNL201, который прошел клинические испытания фазы 1b, и DNL151, который находится в фазе 1 и фазе 1b клинических испытаний болезни Паркинсона. plus de détailsParamètres de base
IPO date
2017-12-08
ISIN
US24823R1059
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 9.13 | 1 |
| P/BV | 2.71 | 6 |
| P/E | 62.94 | 1 |
Efficacité
| Nom | Signification | Grade |
| ROA | -33.45 | 0 |
| ROE | -37.4 | 0 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | -0.1174 | 10 |
| Debt/Ratio | 0.0354 | 10 |
| Debt/Equity | 0.1175 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 1137.94 | 10 |
| Rentabilité Ebitda, % | -761.74 | 0 |
| Rentabilité EPS, % | -507.23 | 0 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 13.42 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 13.91 $ | 0 $ | 0 $ | -3.52 % | 0 % | 0 % |
| common.calendar.number_days.30d | 15.49 $ | 13.42 $ | 14.29 $ | -13.36 % | 0 % | 0 % |
| common.calendar.number_days.90d | 20.67 $ | 11.47 $ | 16.65 $ | -35.07 % | 0 % | 0 % |
| common.calendar.number_days.180d | 24.68 $ | 11.47 $ | 23.59 $ | -45.62 % | 0 % | 0 % |
| common.calendar.number_days.1y | 19.21 $ | 11.47 $ | 31.58 $ | -30.14 % | 0 % | 0 % |
| common.calendar.number_days.3y | 25.23 $ | 11.47 $ | 38.72 $ | -46.81 % | 0 % | 0 % |
| common.calendar.number_days.5y | 23.39 $ | 11.47 $ | 93.56 $ | -42.63 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0 $ | 11.47 $ | 93.56 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 23.29 $ | 11.47 $ | 23.59 $ | -42.38 % | 0 % | 0 % |
Délit d'initié
Principaux propriétaires
Contenu dans l'ETF
| ETF | Partager, % | Rentabilité pour l'année, % | Commission, % |
FINEX JAPAN UCITS ETF
|
335 | 155.8 | 0.9 |
| PSYK ETF | 4.15 | 0 | 0.75 |
| Future Tech ETF | 0.42765 | -18.13 | 0.35 |
| Principal Healthcare Innovators ETF | 0.42765 | -3.92 | 0.35 |
| iShares Morningstar Small-Cap Value ETF | 0.08616 | 173.73 | 0.06 |
| iShares Morningstar Small-Cap ETF | 0.08122 | 295.15 | 0.25 |
| iShares Morningstar Small-Cap Growth ETF | 0.07625 | 604.45 | 0.06 |
| 48,61 | 172,44 | 0,39 |
|---|
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Dr. Ryan J. Watts Ph.D. | Co-Founder, President, CEO & Director | 1.04M | 1976 (49 années) |
| Dr. Alexander O. Schuth M.D. | Co-Founder, CFO, COO & Secretary | 737.2k | 1973 (52 année) |
| Mr. Tyler M. Nielsen | Senior Vice President of Corporate Finance | N/A | 1978 (47 années) |
| Dr. Dana Andersen | Chief Technical and Manufacturing Officer | N/A | |
| Dr. Laura Hansen | Vice President of Investor Relations | N/A | |
| Mr. Chris Walsh | General Counsel | N/A | |
| Dr. Marc Tessier-Lavigne Ph.D. | Co-Founder & Independent Director | 58.23k | 1960 (65 années) |
| Dr. Carole Ho M.D. | Chief Medical Officer & Head of Development | 737.2k | 1973 (52 année) |
| Mr. Joe Lewcock Ph.D. | Chief Scientific Officer | N/A | |
| Mr. Mark Rowen | Vice President of Corporate Development | N/A |
Informations sur l'entreprise
Adresse: United States, South San Francisco, 161 Oyster Point Boulevard - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.denalitherapeutics.com
Site web: https://www.denalitherapeutics.com
